Cargando…
Extensive Cerebral Venous Sinus Thrombosis (CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine without Thrombotic Thrombocytopenia Syndrome (TTS) in a Healthy Woman
Patient: Female, 28-year-old Final Diagnosis: Cerebral venous sinus thrombosis (CVST) post first dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine Symptoms: Headache Medication:— Clinical Procedure: CTV • Laboratory Specialty: Hematology • Immunology • Infectious Diseases • Neurology OBJECTIVE:...
Autores principales: | Alhashim, Ali, Hadhiah, Kawther, khalifah, Zahra Al, Alhaddad, Fatimah Mohammed, Al ARhain, Sara A., Bin Saif, Faisal H., Abid, Ahmad, Gamdi, Omar Al, Alsulaiman, Feras, AlQarni, Mustafa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842441/ https://www.ncbi.nlm.nih.gov/pubmed/35136010 http://dx.doi.org/10.12659/AJCR.934744 |
Ejemplares similares
-
No evidence of TTS risk with Pfizer/BioNTech's COVID-19 vaccine
Publicado: (2021) -
A racing heart post‐Pfizer/BioNTech BNT162b2
por: Teo, Hooi Khee, et al.
Publicado: (2022) -
Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
por: Hamada, Yohhei
Publicado: (2021) -
Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech
por: Okada, Yusuke, et al.
Publicado: (2021) -
Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
por: Li, Chunfeng, et al.
Publicado: (2022)